English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Aim: to compare the mid-term results of treatment of patients with acute attack of moderate and severe ulcerative colitis receiving standard anti-inflammatory therapy and integrated anti-inflammatory therapy using allogeneic culture of mesenchymal stem cells of bone marrow. Materials and methods. Patients with acute attack of ulcerative colitis were divided into two groups. The first group of patients with UC (n=12) in addition to standard anti-inflammatory therapy, received the culture of mesenchymal stem cells (MSC). The second group of patients (n=10) received standard anti-inflammatory therapy with 5-aminosalicylic acid (5-ASA) and glucocorticosteroids (GCS). The clinical activity of UC was assessed on a scale D. Rachmilewitz endoscopic picture was assessed on a scale of Mayo. The duration of remission in groups of patients was estimated by the method of Kaplan-Meier. Results. The original index of Rachmilevitz and the index of Mayo in both groups were comparable. In a year from the start of the study, the risk of recurrence of ulcerative colitis, duration of remission, indices of clinical and endoscopic activity in both groups of patients were comparable. After two years, the effectiveness of anti-inflammatory therapy on major indicators was higher in the group of patients treated with MSC. However, after 3 years of follow-up in both groups clinical and endoscopic indices showed no significant differences. Conclusion. The introduction of a culture of MSC increases the effectiveness of anti-inflammatory therapy in patients with acute attack of ulcerative colitis, increases the duration of disease remission, reduces to 3 times the risk of attack within 2 years of observation

The use of mesenchymal stem cells of bone marrow in the treatment of patients with acute attack of ulcerative colitis